TP53 and breast carcinoma: A novel benzofuran–pyrazol thiazolidinone hybrid exhibited strong EGFR inhibition and G1/S arrest in HeLa cells, with p53‐dependent upregulation of Bax/Bcl‐2 and caspases‐3/7, suggesting its potential for application in breast cancer therapy [34].